With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks ...

Cambridge, Massachusetts-based Vor Bio has confirmed that it will halt clinical and manufacturing operations, including its ...

For instance, studies have shown that approximately 25% of adults with diabetes reported rationing insulin in the previous ...

The GLISTEN trial of GSK's linerixibat has shown that the oral ileal bile acid transporter (IBAT inhibitor was signposted as ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...

Moreover, Downing Street has indicated that the UK will receive "preferential treatment in any further tariffs imposed" as ...

AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the Trump administration. On a conference call to discuss AbbVie's first ...

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in 2023, earning $22.2 billion by 2025, according to new research by GlobalData.

As a psychiatric provider working with people from all walks of life, I’ve seen how serious mental health conditions, particularly bipolar I disorder (BD-I), can present differently depending on ...

Castor bean tick (Ixodes ricinus) female from Hochholz-Kapellenbruch, Germany. There is currently no approved treatment for intracerebral haemorrhagic (ICH) stroke, but Belgian start-up Bioxodes ...

Click Therapeutics' digital therapeutic (DTx) CT-132 has been approved by the FDA, becoming the first treatment of its type in the US for preventing attacks in people with episodic migraine.

One area in which March proved to be a busy month was in Board appointments, where both Boards of Directors and Advisory Boards saw a number of interesting additions. Here’s a round-up of the ...